This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Merck B.V., The Netherlands.
Reference
Michels RE, et al. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Applied Health Economics and Health Policy : 23 Aug 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00500-8
Rights and permissions
About this article
Cite this article
Cladribine tablets cost effective in relapsing-remitting MS. PharmacoEcon Outcomes News 836, 7 (2019). https://doi.org/10.1007/s40274-019-6180-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6180-3